[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100410442":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":18,"responsibleParty":37,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Case Comprehensive Cancer Center","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Gregory Cooper, MD","University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[14],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","1-800-641-2422","gregory.cooper@uhhospitals.org",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center","RECRUITING","Cleveland","Ohio","44106","United States","US",{"type":28,"coordinates":29},"Point",[30,31],-81.69541,41.4995,{"lat":31,"lon":30},[34],{"name":10,"role":15,"phone":35,"phoneExt":7,"email":36},"800-641-2422","CTUReferral@UHhospitals.org",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100410442","the-utility-and-feasibility-of-mt-sdna-as-a-surveillance-procedure-in-colorectal-cancer-survivors-100410442",false,"NCT04624555","The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors","Inclusion Criteria:\n\n* Diagnosis of stage I, II or III adenocarcinoma of the colon or rectum\n* Receipt of preoperative colonoscopy\n* Receipt of bowel resection; use of adjuvant chemotherapy or radiation therapy as clinically indicated\n\nExclusion Criteria:\n\n* Stage IV colorectal cancer\n* Surgical treatment with subtotal colectomy or total proctocolectomy\n* Diagnosis of inflammatory bowel disease (ulcerative colitis or Crohn's disease)\n* Diagnosis of polyposis syndrome including Lynch syndrome or familial polyposis\n* Presence of advanced adenomas (1 cm or larger, villous features and\u002For high grade dysplasia) that were not removed at the preoperative colonoscopy or contained in the resection specimen.\n* Inability to provide informed consent\n* Inability to understand spoken and written English\n* Medical comorbidities that would be contraindications to sedation or that would preclude any benefit of routine surveillance post-resection. These would be at the discretion of the participant's providers.","ALL","18 Years",{"count":48,"type":49},50,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to determine whether testing of stool for a panel of markers will enable us to detect polyps and cancer compared to standard testing.",[53,54,55,56,57],"Adenocarcinoma of the Colon","Adenocarcinoma of the Rectum","Stage I Colorectal Cancer","Stage II Colorectal Cancer","Stage III Colorectal Cancer","2026-04-06",{"date":60,"type":61},"2026-04-09","ACTUAL",{"date":63,"type":61},"2022-10-31",{"date":65,"type":49},"2026-09-01",{"name":5,"class":6},1]